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This workshop was fully subscribed and was attended by an 
audience of approximately 150 people, who listened to 29 
short talks given by researchers from the UK and ROI. The 
intention of the workshop was to act as a showcase for the 
research on SARS- CoV-2 and COVID-19 currently under-
way, but also to provide a platform for people to present their 
future plans and seek input and advice. It was intended there-
fore to bring together the various researchers and interested 
parties to promote exchange of ideas; in particular, it sought 
to highlight opportunities for collaborative work and sharing 
of reagents. In that regard, as well as presentations on the 
biology of the virus, Arvind Patel (CVR, Glasgow) and Yann 
Le Duff (NIBSC) described extensive open resources that are 
available for researchers. More details can be found at https:// 
mrcppu- covid. bio/ and www. nibsc. org/ cfar.
A recurrent theme throughout the day was the challenge 
encountered by many groups in starting research projects 
on SARS- CoV-2. These included seeking permission for the 
work from the Health and Safety Executive, obtaining virus 
stocks and then establishing safe working practices and robust 
protocols for propagation and titration of virus, and of course 
securing funding for the work. To compound these obsta-
cles there was the overarching issue of lab closure following 
lockdown, although with a few exceptions this restriction 
was lifted for COVID- related research. The extraordinary 
progress presented during the workshop is a testament to the 
dedication and hard work of the virology community.
A second thread that ran through the workshop was that very 
few labs in the UK/ROI had previous experience in working 
with coronaviruses. In general groups had rapidly repurposed 
their activity and applied their skills and expertise to SARS-
 CoV-2. Again this flexibility and willingness to tackle new 
challenges reflects well on the community.
The workshop started with a session on the molecular and 
cellular biology of SARS- CoV-2. The challenge of manipu-
lating the ~30 kb cDNA of the viral genome was highlighted 
by Andrew Davidson from Bristol who described their 
approach to this problem and successful generation of 
cDNA for infectious virus and subgenomic replicons. These 
reagents were already feeding into collaborative work with, 
for example, Wendy Barclay (Imperial) to understand the 
role of proteolytic cleavage of the spike protein by furin in 
SARS- CoV-2 transmission, and Hazel Stewart (Cambridge) 
who described the identification of a novel protein ORF3c and 
initial progress towards its characterization.
Other labs have used virus obtained from clinical samples: Greg 
Towers (UCL) characterized the innate immune response to 
virus infection in Calu-3 lung epithelial cells; Zania Stamataki 
(Birmingham) is investigating aspects of virus infection and 
transmission; Sharon Brookes (APHA) has established a ferret 
model to study pathogenesis; lastly, David Matthews (Bristol) 
described ‘omics- based approaches to understanding replica-
tion, host- cell interactions and pathogenesis, using Nanopore 
technology to directly sequence mRNA from infected cells. 
Connor Bamford (Belfast) described the establishment of a 
repurposing drug screen to identify small molecule inhibi-
tors of SARS- CoV-2. Other therapeutic approaches included 
Gemma Swinscoe (Leeds) who has established an assay for 
viroporin activity of the E protein and Catherine Adamson 
(St Andrews) who is using a cell- based screen based on the 
inhibition of virus- induced cytopathic effect.
The latter two talks highlighted the fact that establishing 
work with SARS- CoV-2 in a BSL3 laboratory is non- trivial 
and time consuming, so many groups presented data derived 
from various model systems. These included lentiviruses 
pseudotyped with the SARS- CoV-2 spike (S) glycoprotein 
which Dalan Bailey (Pirbright) used to show that S could 
bind to the receptor ACE2 protein of diverse species. Others 
expressed individual viral proteins: Gill Elliott (Surrey) looked 
at translocation of envelope proteins, Rachel Ulferts (Crick) 
and Helena Maier (Pirbright) were interested in membrane 
trafficking and structures.
The SARS- CoV-2 genome was a focus for several groups: 
Emma Thomson (CVR, Glasgow) used state- of- the- art 
sequencing to track multiple introductions of SARS- CoV-2 
into Scotland before travel restrictions were applied. Bioin-
formatics approaches allowed Peter Simmonds (Oxford) and 
Colin Sharp (Edinburgh) to analyse the epigenetics of the 
virus (RNA editing and CpG/UpA frequencies).
Analysis of serological responses was an important theme: 
Katie Doores (KCL) looked at longitudinal antibody responses 
showing that disease severity correlated with neutralization 
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activity but not the kinetics of the response. Maia Kavanagh 
Williamson (Bristol) and Alex Tarr (Nottingham) also exam-
ined antibody responses, describing evidence for neutralizing 
and virus entry- enhancing antibodies during severe infection. 
Suzy Pickering (KCL) and Abbie Bown (PHE) evaluated a 
range of commercially available serology assays. On a related 
subject, Nicola Stonehouse (Leeds) described a VLP platform 
for antigen presentation that was being applied to SARS-
 CoV-2, and Simon Graham (Pirbright) provided an update 
on evaluation of candidate vaccines in pigs, highlighting that a 
prime- boost protocol was more efficacious than a single dose.
Other diverse approaches to understanding SARS- CoV-2 
biology or working towards therapies included Stergios 
Moschos (Northumbria) who described a novel hand- held 
system to detect viruses (and other pathogens or substances) 
in exhaled breath or other aerosols, Abeer Shaalan (KCL) who 
is interested in caspase inhibition as a method to prevent the 
cytokine storm, and Chris Coleman (Nottingham) who is 
seeking to extrapolate his work on MERS protein functions 
to SARS- CoV-2.
A final discussion revealed great enthusiasm to hold further 
events, perhaps taking place over two half- day sessions to 
avoid Zoom fatigue. Providing a forum to share ideas, proto-
cols and reagents/systems was seen as a critical outcome 
and the Microbiology Society was identified as the obvious 
organization to facilitate this. All agreed that this should be 
expedited.
Mark Harris, University of Leeds, on behalf of the other 
members of the organizing committee:
Peter O’Hare, Imperial College London
Paul Kellam, Imperial College London
Lindsay Broadbent, Queens University Belfast
Steve Griffin, University of Leeds
Five reasons to publish your next article with a Microbiology Society journal
1.  The Microbiology Society is a not-for-profit organization.
2.  We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3.   Our journals have a global readership with subscriptions held in research institutions around  
the world.
4.  80% of our authors rate our submission process as ‘excellent’ or ‘very good’.
5.  Your article will be published on an interactive journal platform with advanced metrics.
Find out more and submit your article at microbiologyresearch.org.
